Skip to main content

Table 3 Risk of COVID-19 among individuals with neurodegenerative diseases, by time since the first diagnosis, compared to individuals without such conditions

From: COVID-19 related outcomes among individuals with neurodegenerative diseases: a cohort analysis in the UK biobank

  No.(%)of Any COVID-19 Odds Ratio No.(%)of Inpatient COVID-19 Odds Ratio No.(%)of COVID-19 related death Odds Ratio
Exposed Unexposed (95% CI) Exposed Unexposed (95% CI) Exposed Unexposed (95% CI)
Time since the first diagnosis of neurodegenerative diseases, years
  < 1 82/309 (26.5) 17,220/93658 (18.4) 2.56 (1.97–3.32) 49/309 (15.9) 5370/93658 (5.7) 2.45 (1.79–3.36) 19/309 (6.1) 986/93658 (1.1) 2.81 (1.73–4.57)
 1–2 289/1009 (28.6) 2.70 (2.34–3.12) 158/1009 (15.7) 2.37 (1.98–2.83) 84/1009 (8.3) 3.92 (3.08–5.01)
 3–4 145/549 (26.4) 2.42 (1.99–2.95) 72/549 (13.1) 1.95 (1.51–2.51) 49/549 (8.9) 4.45 (3.25–6.09)
  ≥ 5 202/750 (26.9) 2.27 (1.92–2.68) 100/750 (13.3) 1.99 (1.60–2.47) 43/750 (5.7) 2.89 (2.08–4.00)
  1. Any COVID-19 includes a positive test result from PHE, or an inpatient diagnosis from UK Biobank inpatient hospital data or a death cause of COVID-19 infection
  2. Odds Ratio (95%) were derived from logistic regression models, which were adjusted for birth year, sex, race/ethnicity, body mass index, smoking, alcohol use, Townsend deprivation index, annual household income, educational attainment, and Charlson Comorbidity Index (dementia excluded)